Who is sponsoring NCT06642038?

NCT06642038 is sponsored by Ye Gu.

What drugs are being tested in NCT06642038?

Interventions in NCT06642038: Transbronchial Endoscopic Thermal Vapor Ablation.

What condition does NCT06642038 study?

NCT06642038 studies Heterogeneous Emphysema.

Is NCT06642038 still recruiting?

NCT06642038 is currently not yet recruiting. Last updated 15 October 2024.

Last reviewed 2024-10-15 · How we verify

NCT06642038

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Transbronchial Bronchoscopic Thermal Vapor Ablation (BTVA) in Heterogeneous Emphysema

Not yet recruiting Last updated 15 October 2024

What this trial tests

trial testing Transbronchial Endoscopic Thermal Vapor Ablation in Heterogeneous Emphysema in 51 participants. Not yet recruiting.

Timeline

13 October 2024

Primary endpoint
1 September 2025

1 September 2026

Quick facts

Lead sponsor	Ye Gu
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	51
Start date	13 October 2024
Primary completion	1 September 2025
Estimated completion	1 September 2026

Drugs / interventions tested

Transbronchial Endoscopic Thermal Vapor Ablation

Conditions studied

Heterogeneous Emphysema — all drugs for Heterogeneous Emphysema →

Sponsor

Ye Gu

Who can join

Adults 40 to 75, any sex, with Heterogeneous Emphysema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Efficacy and Safety of Transbronchial BTVA in Heterogeneous Emphysema: A Prospective, Single-Arm, Multicenter Clinical Study

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06642038 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ye Gu
Last refreshed: 15 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06642038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing